JPRN-jRCT2080221059未知3 期
A Phase 3 Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of D961H (20 mg Once Daily) Versus Placebo for Prevention of Gastric and/or Duodenal Ulcers Associated With Continuous Low-dose Aspirin (LDA) Use
适应症
试验速览
- 阶段
- 3 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Provision of written informed consent before starting the study-related procedures and examinations
- •2. Patients who have the history of gastric and/or duodenal ulcer
- •3. A diagnosis of a chronic condition (angina pectoris, myocardial infarction and ischemic cerebrovascular disorder, etc., requiring prevention of thrombosis or embolism) which requires taking the prescribed LDA during the study treatment period
排除标准
- •1. Having gastric or duodenal ulcer (except for ulcer scar)
- •2. History of esophageal, gastric or duodenal surgery, except for simple closure of perforation
研究者
相似试验
进行中（未招募）
1 期
A study to look at the efficacy and safety of ALN TTRSC in patients with an inherited condition that causes certain protein molecules to deposit in the heart.Transthyretin (TTR) mediated familial amyloidotic cardiomyopathy (FAC)MedDRA version: 18.1Level: PTClassification code 10016202Term: Familial amyloidosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2014-003835-20-GBAlnylam Pharmaceuticals, Inc.200
进行中（未招募）
1 期
A study to look at the efficacy and safety of ALN TTRSC in patients with an inherited condition that causes certain protein molecules to deposit in the heartTransthyretin (TTR) mediated familial amyloidotic cardiomyopathy (FAC)MedDRA version: 19.0Level: PTClassification code 10016202Term: Familial amyloidosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2014-003835-20-DEAlnylam Pharmaceuticals, Inc.200
进行中（未招募）
1 期
A study to look at the efficacy and safety of ALN TTRSC in patients with an inherited condition that causes certain protein molecules to deposit in the heartTransthyretin (TTR) mediated familial amyloidotic cardiomyopathy (FAC)MedDRA version: 18.1Level: PTClassification code 10016202Term: Familial amyloidosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2014-003835-20-BEAlnylam Pharmaceuticals, Inc.200
进行中（未招募）
1 期
A study to look at the efficacy and safety of ALN TTRSC in patients with an inherited condition that causes certain protein molecules to deposit in the heartEUCTR2014-003835-20-SEAlnylam Pharmaceuticals, Inc.200
进行中（未招募）
1 期
A study to look at the efficacy and safety of ALN TTRSC in patients with an inherited condition that causes certain protein molecules to deposit in the heartTransthyretin (TTR) mediated familial amyloidotic cardiomyopathy (FAC)MedDRA version: 18.0Level: PTClassification code 10016202Term: Familial amyloidosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2014-003835-20-ESAlnylam Pharmaceuticals, Inc.200